Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Lorenza Rimassa
369 views
September 20, 2024
Chapters
Introduction & Presentation Overview
00:00
First-Line Immunotherapy in HCC
00:36
HIMALAYA Trial & STRIDE Regimen Results
02:47
CheckMate 9DW Trial Insights
05:33
Selecting First-Line Therapy & Biomarkers
08:20
Sequencing After Immunotherapy
11:57
Treating Special Populations
16:25
Conclusions & Future Perspectives
17:10
Comments 0
Login to view comments.
Click here to Login